Abstract
Aim: Several studies reported the accompaniment of severe COVID-19 with comorbidities. However, there is not a systematic evaluation of all aspects of this association. Therefore, this meta-analysis aimed to assess the association between all underlying comorbidities in COVID-19 infection severity. Methods: Electronic literature search was performed via scientific search engines. After the removal of duplicates and selection of articles of interest, 28 studies were included. A fixed-effects model was used; however, if heterogeneity was high (I2 > 50%) a random-effects model was applied to combine the data. Results: A total of 6,270 individuals were assessed (1,615 severe and 4,655 non-severe patients). The median age was 63 (95% confidence interval [CI]: 49–74) and 47 (95% CI: 19–63) years in the severe and non-severe groups, respectively. Moreover, about 41% of patients had comorbidities. Severity was higher in patients with a history of cerebrovascular disease: OR 4.85 (95% CI: 3.11–7.57). The odds of being in a severe group increase by 4.81 (95% CI: 3.43–6.74) for a history of cardiovascular disease (CVD). This was 4.19 (95% CI: 2.84–6.19) for chronic lung disease and 3.18, 95% CI: 2.09–4.82 for cancer. The odds ratios of diabetes and hypertension were 2.61 (95% CI: 2.02–3.3) and 2.37 (95% CI: 1.80–3.13), respectively. Conclusions: The presence of comorbidities is associated with severity of COVID-19 infection. The strongest association was observed for cerebrovascular disease, followed by CVD, chronic lung disease, cancer, diabetes, and hypertension.
References
1.
Leung
C
. Clinical features of deaths in the novel coronavirus epidemic in China
. Rev Med Virol
. 2020 May
;30
(3
):e2103
.2.
Honardoost
M
, Ghavideldarestani
M
, Khamseh
ME
. Role of vitamin D in pathogenesis and severity of COVID-19 infection
. Arch Physiol Biochem
. 2020 Oct 30
;1
–7
.3.
Coronavirus disease (COVID-19) Weekly Epidemiological Update. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=9e354665_6
.4.
Wang
D
, Hu
B
, Hu
C
, Zhu
F
, Liu
X
, Zhang
J
, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
. JAMA
. 2020 Mar 17
;32
(11
):1061
–9
.5.
AghiliHonardoost
RM
, Khamseh
ME
. COVID-19: case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
. Med J Islam Repub Iran
. 2020
;34
(1
).6.
Yang
J
, Zheng
Y
, Gou
X
, Pu
K
, Chen
Z
, Guo
Q
, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis
. Int J Infect Dis
. 2020
.7.
Huang
C
, Wang
Y
, Li
X
, Ren
L
, Zhao
J
, Hu
Y
, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
. Lancet
. 2020
;395
(10223
):497
–506
. .8.
Zhang
J
, Dong
X
, Cao
YY
, Yuan
Y
, Yang
Y
, Yan
Y
, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China
. Allergy
; 2020
.9.
Asefi
H
, Safaie
A
. The role of chest CT scan in diagnosis of COVID-19
. Adv J Emerg Med
. 2020
;4
(2s
):e64
–e
.10.
Brown
SM
, Dean
NC
. Defining severe pneumonia
. Clin Chest Med
. 2011
;32
(3
):469
–79
. .11.
Li
K
, Wu
J
, Wu
F
, Guo
D
, Chen
L
, Fang
Z
, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia
. Invest Radiol
. 2020 Jun
;55
(6
):327
–31
.12.
Li
Y-K
, Peng
S
, Li
L-Q
, Wang
Q
, Ping
W
, Zhang
N
, et al. Clinical and transmission characteristics of Covid-19: a retrospective study of 25 cases from a single thoracic surgery department
. Curr Med Sci
. 2020 Apr
;40
(2
):295
–300
.13.
Liguoro
I
, Pilotto
C
, Bonanni
M
, Ferrari
ME
, Pusiol
A
, Nocerino
A
, et al. SARS-COV-2 infection in children and newborns: a systematic review
. Eur J Pediatr
. 2020
;179
(7
):1029
–46
. .14.
Organization WH
. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020
. World Health Organization
; 2020
.15.
Zhang
JJ
, Lee
KS
, Ang
LW
, Leo
YS
, Young
BE
. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis
. Clin Infect Dis
. 2020 Nov 19
;71
(16
):2199
–206
. .16.
Tang
X
, Du
R
, Wang
R
, Cao
T
, Guan
L
, Yang
C
, et al. Comparison of hospitalized patients with acute respiratory distress syndrome caused by COVID-19 and H1N1
. Chest
. 2020
.17.
Control CfD, Control CfD, Prevention. Morbidity and mortality weekly report: MMWR US Department of Health, Education, and Welfare, Public Health Service; 1988
.18.
Wang
T
, Du
Z
, Zhu
F
, Cao
Z
, An
Y
, Gao
Y
, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19
. Lancet
. 2020
;395
(10228
):e52
. .19.
Guo
W
, Li
M
, Dong
Y
, Zhou
H
, Zhang
Z
, Tian
C
, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19
.Diabetes Metab Res Rev
. 2020 Mar 31
;e3319
.20.
Deng
Y
, Liu
W
, Liu
K
, Fang
Y-Y
, Shang
J
, Wang
K
, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study
. Chin Med J
. 2020 Jun 5
;133
(11
):1261
–7
.21.
Lippi
G
, Henry
BM
. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)
. Respir Med
. 2020 Jun
;167
:105941
.22.
Lippi
G
, Wong
J
, Henry
BM
. Hypertension and its severity or mortality in coronavirus disease 2019 (COVID-19): a pooled analysis
. Pol Arch Intern Med
. 2020 Apr 30
;130
(4
):304
–9
.23.
Mao
L
, Jin
H
, Wang
M
, Hu
Y
, Chen
S
, He
Q
, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
. JAMA Neurol
. 2020 Jun 1
;77
(6
):683
–90
.24.
Clerkin
KJ
, Fried
JA
, Raikhelkar
J
, Sayer
G
, Griffin
JM
, Masoumi
A
, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease
. Circulation
. 2020
.25.
Shi
S
, Qin
M
, Shen
B
, Cai
Y
, Liu
T
, Yang
F
, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
. JAMA Cardiol
. 2020 Jul 1
;5
(7
):802
–10
.26.
Wu
Z
, McGoogan
JM
. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention
. JAMA
. 2020 Apr 7
;323
(13
):1239
–42
.27.
Jain
V
, Yuan
J-M
. Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection
. medRxiv
. 2020
.28.
Jazieh
AR
, Alenazi
TH
, Alhejazi
A
, Al Safi
F
, Al Olayan
A
. Outcome of oncology patients infected with coronavirus
. JCO Glob Oncol
. 2020
;6
:471
–5
. .29.
Liang
W
, Guan
W
, Chen
R
, Wang
W
, Li
J
, Xu
K
, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
. Lancet Oncol
. 2020
;21
(3
):335
–7
. .30.
Gupta
R
, Ghosh
A
, Singh
AK
, Misra
A
. Clinical considerations for patients with diabetes in times of COVID-19 epidemic
. Diabetes Metab Syndr
. 2020 May–Jun
;14
(3
):211
–2
. .31.
Fadini
G
, Morieri
M
, Longato
E
, Avogaro
A
. Prevalence and impact of diabetes among people infected with SARS-CoV-2
. J Endocrinol Invest
. 2020 Jun
;43
(6
):867
–9
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
